Daming Zhou

Centre for Human Genetics — United Kingdom

Medicine · Health Sciences

28h-index8.0kcitations76works9.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(50), COVID-19 Clinical Research Studies(17), Monoclonal and Polyclonal Antibodies Research(12), vaccines and immunoinformatics approaches(11), Influenza Virus Research Studies(10)

Publications76 total

Amino acid and viral binding by the high-affinity Cationic Amino acid Transporter 1 (CAT1) from Mus musculus
Nature Communications·2026Open Access
Dimensionality Enhanced Out-of-Plane Spin Currents in NbIrTe$_4$ for Efficient Field-Free Switching of Perpendicular Magnetization
arXiv (Cornell University)·2025Open Access
Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition
Proceedings of the National Academy of Sciences·2024· 13 citedOpen Access
Amino acid and viral binding by the high-affinity Cationic Amino acidTransporter 1 (CAT1) from Mus musculus
2024Open Access
Non-O1, Non-O139 Vibrio cholerae Bacteremia in an Autoimmune Pancreatitis Patient
Case Reports in Infectious Diseases·2024Open Access
A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity
Cell Reports Medicine·2024· 27 citedOpen Access
Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
Nature Communications·2024· 14 citedOpen Access
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
Nature Communications·2024· 21 citedOpen Access
Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
Research Square (Research Square)·2023Open Access
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
The Lancet Infectious Diseases·2023· 41 cited
Cooperativity and induced oligomerisation control the interaction of SARS-CoV-2 with its cellular receptor and patient-derived antibodies
2023· 2 citedOpen Access
Broadly neutralizing antibodies against COVID-19
Current Opinion in Virology·2023· 23 citedOpen Access
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
Nature Communications·2023· 56 citedOpen Access
Isolation of a pair of potent broadly neutralizing mAb binding to RBD and SD1 domains of SARS-CoV-2
2023· 2 citedOpen Access
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Cell Reports·2023· 42 citedOpen Access
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
Cell Reports·2022· 61 citedOpen Access
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
Cell Discovery·2022· 4 citedOpen Access
Switching of Receptor Binding Poses between Closely Related Enteroviruses
Viruses·2022· 2 citedOpen Access
Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
Cell Discovery·2022· 6 citedOpen Access
Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2
2022· 6 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

David I. Stuart(42), Jingshan Ren(39), Elizabeth E. Fry(36), Helen M. E. Duyvesteyn(33), Gavin Screaton(30), Juthathip Mongkolsapaya(28), Piyada Supasa(24), Yuguang Zhao(24), Helen M. Ginn(23), Chang Liu(22), Jiandong Huo(21), Neil G. Paterson(21), Miles W. Carroll(20), Alexander J. Mentzer(19), Paul Klenerman(19), Rungtiwa Nutalai(17), Susanna Dunachie(17), Alain Townsend(16), Tiong Kit Tan(16), Aekkachai Tuekprakhon(15)